ES2571792T3 - Neurotoxina botulínica A2 para su uso en el tratamiento de la hiperactividad muscular en presencia de anticuerpos neutralizantes de tipo A1 - Google Patents

Neurotoxina botulínica A2 para su uso en el tratamiento de la hiperactividad muscular en presencia de anticuerpos neutralizantes de tipo A1

Info

Publication number
ES2571792T3
ES2571792T3 ES09726893T ES09726893T ES2571792T3 ES 2571792 T3 ES2571792 T3 ES 2571792T3 ES 09726893 T ES09726893 T ES 09726893T ES 09726893 T ES09726893 T ES 09726893T ES 2571792 T3 ES2571792 T3 ES 2571792T3
Authority
ES
Spain
Prior art keywords
type
treatment
neutralizing antibodies
botulinum neurotoxin
muscle hyperactivity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09726893T
Other languages
English (en)
Inventor
Shinji Nakahira
Yasushi Torii
Yoshitaka Goto
Miho Shinmura
Satomi Munechika
Sachio Okuda
Shunji Kozaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemo Sero Therapeutic Research Institute Kaketsuken
Original Assignee
Chemo Sero Therapeutic Research Institute Kaketsuken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeutic Research Institute Kaketsuken filed Critical Chemo Sero Therapeutic Research Institute Kaketsuken
Application granted granted Critical
Publication of ES2571792T3 publication Critical patent/ES2571792T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un medicamento que comprende como ingrediente activo la neurotoxina de tipo A de 150 kDa de Clostridium botulinum de tipo A2 (NTX A2) para su uso en el tratamiento de una enfermedad con hiperactividad muscular para su uso en un paciente que tiene un anticuerpo neutralizante frente a una toxina botulínica de tipo A1.
ES09726893T 2008-03-31 2009-03-31 Neurotoxina botulínica A2 para su uso en el tratamiento de la hiperactividad muscular en presencia de anticuerpos neutralizantes de tipo A1 Active ES2571792T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008092145 2008-03-31
PCT/JP2009/056613 WO2009123174A1 (ja) 2008-03-31 2009-03-31 A2型ボツリヌス神経毒素製剤

Publications (1)

Publication Number Publication Date
ES2571792T3 true ES2571792T3 (es) 2016-05-26

Family

ID=41135546

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09726893T Active ES2571792T3 (es) 2008-03-31 2009-03-31 Neurotoxina botulínica A2 para su uso en el tratamiento de la hiperactividad muscular en presencia de anticuerpos neutralizantes de tipo A1

Country Status (5)

Country Link
US (2) US20110033431A1 (es)
EP (1) EP2283849B1 (es)
JP (1) JPWO2009123174A1 (es)
ES (1) ES2571792T3 (es)
WO (1) WO2009123174A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9278133B2 (en) * 2006-10-27 2016-03-08 The Chemo-Sero-Therapeutic Research Institute Highly purified type A botulinum toxin preparation from infant botulism pathogen
US20110033431A1 (en) * 2008-03-31 2011-02-10 The Chemo-Sero-Therapeutic Research Institute Type a2 botulinum toxin preparation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122009000066I2 (de) * 1993-06-10 2010-12-30 Allergan Inc Behandlung von neuromuskulären Störungen und Zuständen mit verschiedenen botulinen Serotypen
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5756468A (en) 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
JPWO2003082315A1 (ja) * 2002-03-29 2005-07-28 財団法人化学及血清療法研究所 筋緊張亢進疾患治療剤
WO2004112821A1 (ja) * 2003-06-20 2004-12-29 Santen Pharmaceutical Co., Ltd. 筋緊張亢進性疾患の治療剤
WO2007125604A1 (ja) 2006-04-28 2007-11-08 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute 神経毒素の定量方法
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US9278133B2 (en) * 2006-10-27 2016-03-08 The Chemo-Sero-Therapeutic Research Institute Highly purified type A botulinum toxin preparation from infant botulism pathogen
US8540987B2 (en) * 2008-01-29 2013-09-24 Institute For Antibodies Co., Ltd. Composition for neutralizing botulinus toxin type-A, and human anti-botulinus toxin type-A antibody
US20110033431A1 (en) * 2008-03-31 2011-02-10 The Chemo-Sero-Therapeutic Research Institute Type a2 botulinum toxin preparation
WO2012047427A2 (en) * 2010-08-31 2012-04-12 The Regents Of The University Of California Antibodies for botulinum neurotoxins

Also Published As

Publication number Publication date
WO2009123174A1 (ja) 2009-10-08
US20130252902A1 (en) 2013-09-26
EP2283849B1 (en) 2016-05-04
US20110033431A1 (en) 2011-02-10
US9623075B2 (en) 2017-04-18
EP2283849A4 (en) 2013-04-10
JPWO2009123174A1 (ja) 2011-07-28
EP2283849A1 (en) 2011-02-16

Similar Documents

Publication Publication Date Title
CO2019009680A2 (es) Anticuerpo anti-gprc5d y molécula que comprende el anticuerpo
NI201000105A (es) Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada.
BR112012022797A2 (pt) composição farmacêutica resistente a álcool, e, método para tratar uma doença com uma formulação de agente ativo resistente a álcool
BR112016016290A2 (pt) Composições farmacêuticas de insulina de ação rápida, conjunto de infusão, sistema de conjunto de infusão e usos de análogos monoméricos ou diméricos de insulina
AR093386A1 (es) Composicion para tratar la diabetes o la diabesidad que comprende un analogo de oxintomodulina y metodo de tratamiento
GT201200313A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
BR112012004806B8 (pt) composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso
BR112014008294A2 (pt) anticorpo anti c-met e usos do mesmo
BRPI0906478B8 (pt) anticorpo anti-nr10, seu uso e composição farmacêutica que o compreende
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
NI201000044A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
BR112014009418A2 (pt) macrociclos peptidomiméticos
ECSP11010975A (es) Método de uso de una cepa de bacillus subtilis para mejorar la salud de animales
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
AR059922A1 (es) Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
ECSP10010322A (es) Anticuerpos contra el virus de la influenza y métodos de uso de los mismos
CR11472A (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
BR112014015851A2 (pt) proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
AR060165A1 (es) Proteina de suero como vehiculo de entrega para un agente activo
ATE534378T1 (de) Titrierung von tapentadol
EA200970237A1 (ru) Применение тенектеплазы для лечения острого ишемического инсульта
CL2008000442A1 (es) Composicion farmaceutica que comprende a un quitosano, un ingrediente activo cosmetico o farmaceutico, y un solvente volatil; y su uso para tratar psoriasis, micosis entre otras enfermedades.
CR20110599A (es) Composiciones farmacéuticamente activas que comprenden moduladores de estrés oxidativo (osm), nuevas entidades químicas, composiciones y usos